Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Yonghe Medical (雍禾医疗) IPO: Fairly Valued

Yonghe Medical (雍禾医疗) Pre-IPO: Sales-Driven Business Model

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Yonghe Medical Group / Equity Capital Markets

<ul>
<li>Yonghe Medical raised HKD 1,357 million (USD 174m) from its global offering and will list on the Hong Kong Stock Exchange on Monday, December 13th.</li>
<li>Despite being a top player in the hair transplant market in China, we don't like its business model and growth prospect.</li>
<li>In this note, we look at the updates since our last note and prior to debut on next Monday. </li>
</ul>


Yonghe Medical raised HKD 1,357 million (USD 174m) from its global offering and will list on the Hong Kong Stock Exchange on Monday, December 13th.
Despite being a top player in the hair transplant market in China, we don't like its business model and growth prospect.
In this note, we look at the updates since our last note and prior to debut on next Monday. 


Yonghe Medical (雍禾医疗) IPO Trading: Likely a Poor Debut Performance